Myriad Genetics, Inc.
NASDAQ:MYGN 3:59:56 PM EDT
Earnings Announcements
Myriad Genetics Reports First Quarter Revenue And Reiterates Guidance For 2022
Published: 05/05/2022 13:25 GMT
Myriad Genetics, Inc. (MYGN) - Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022.
Q1 GAAP Loss per Share $0.26.
Q1 Revenue Rose 11 Percent to $164.9 Million.
Qtrly Adjusted Net Loss per Share $0.03.
Q1 Earnings per Share View $-0.07, Revenue View $156.6 Million -- Refinitiv Ibes Data (analyst estimates).
Q1 GAAP Loss per Share $0.26.
Q1 Revenue Rose 11 Percent to $164.9 Million.
Qtrly Adjusted Net Loss per Share $0.03.
Q1 Earnings per Share View $-0.07, Revenue View $156.6 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $172.12 Million
Adjusted EPS is expected to be $0.03
Next Quarter Revenue Guidance is expected to be $170.09 Million
Next Quarter EPS Guidance is expected to be $0.01
More details on our Analysts Page.
Adjusted EPS is expected to be $0.03
Next Quarter Revenue Guidance is expected to be $170.09 Million
Next Quarter EPS Guidance is expected to be $0.01
More details on our Analysts Page.